Laboratory and clinical studies on S-1108 in the pediatric field

H. Akita, T. Yokota, K. Sunakawa, S. Iwata, Y. Satoh

Research output: Contribution to journalArticle

Abstract

Laboratory and Clinical Studies on S-1108, a new oral cephem antibiotic, were carried out to evaluate its usefulness at a dose between 2 and 4 mg/kg a day for 7 to 14 days in the pediatric field. 1) Pharmacokinetic studies. S- 1108 at a dose of 2 mg/kg was administered to evaluate the pharmacokinetic parameters in 1 subject. C(max), T1/2 and AUC were 0.69 hour, 1.42 hours and 2.15 μg·hr/ml, respectively. 2) Antimicrobial activities. MICs against various clinically isolated organisms (Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Branhamella catarrhalis, Escherichia coli and Haemophilus influenzae) were determined. The MIC values of S-1006 were similler to those of cefteram, the MICs against S. pyogenes, and H. influenzae were ≤0.025 and 0.10 μg/ml, respectively. 3) Clinical studies. S-1108 was administered to patients with various pediatrics infections in 34 cases (upper respiratory tract infections: 12 cases, lower respiratory tract infections: 5 cases, urinary tract infections: 9 cases, skin and soft tissue infection: 6 cases, otitis media: 2 cases). Clinical efficacy rate was evaluated according to 'Standard of clinical evaluation in pediatrics field'. The responses were all good or excellent. 4) Side reactions. There were no serious adverse reactions in any cases. The above results suggest that S- 1108 is potent effective and safe agent in the pediatric field at a dose between 2~4 mg/kg (t.i.d.) a day.

Original languageEnglish
Pages (from-to)967-977
Number of pages11
JournalJapanese Journal of Antibiotics
Volume46
Issue number11
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

S 1108
Pediatrics
Streptococcus pyogenes
Haemophilus influenzae
Respiratory Tract Infections
Pharmacokinetics
Moraxella (Branhamella) catarrhalis
Soft Tissue Infections
Otitis Media
Streptococcus pneumoniae
Urinary Tract Infections
Area Under Curve
Staphylococcus aureus
Escherichia coli
Anti-Bacterial Agents
Skin
Clinical Studies
Infection

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Akita, H., Yokota, T., Sunakawa, K., Iwata, S., & Satoh, Y. (1993). Laboratory and clinical studies on S-1108 in the pediatric field. Japanese Journal of Antibiotics, 46(11), 967-977.

Laboratory and clinical studies on S-1108 in the pediatric field. / Akita, H.; Yokota, T.; Sunakawa, K.; Iwata, S.; Satoh, Y.

In: Japanese Journal of Antibiotics, Vol. 46, No. 11, 1993, p. 967-977.

Research output: Contribution to journalArticle

Akita, H, Yokota, T, Sunakawa, K, Iwata, S & Satoh, Y 1993, 'Laboratory and clinical studies on S-1108 in the pediatric field', Japanese Journal of Antibiotics, vol. 46, no. 11, pp. 967-977.
Akita H, Yokota T, Sunakawa K, Iwata S, Satoh Y. Laboratory and clinical studies on S-1108 in the pediatric field. Japanese Journal of Antibiotics. 1993;46(11):967-977.
Akita, H. ; Yokota, T. ; Sunakawa, K. ; Iwata, S. ; Satoh, Y. / Laboratory and clinical studies on S-1108 in the pediatric field. In: Japanese Journal of Antibiotics. 1993 ; Vol. 46, No. 11. pp. 967-977.
@article{39d9275f7b714ce88fbadb98eb4a3e0f,
title = "Laboratory and clinical studies on S-1108 in the pediatric field",
abstract = "Laboratory and Clinical Studies on S-1108, a new oral cephem antibiotic, were carried out to evaluate its usefulness at a dose between 2 and 4 mg/kg a day for 7 to 14 days in the pediatric field. 1) Pharmacokinetic studies. S- 1108 at a dose of 2 mg/kg was administered to evaluate the pharmacokinetic parameters in 1 subject. C(max), T1/2 and AUC were 0.69 hour, 1.42 hours and 2.15 μg·hr/ml, respectively. 2) Antimicrobial activities. MICs against various clinically isolated organisms (Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Branhamella catarrhalis, Escherichia coli and Haemophilus influenzae) were determined. The MIC values of S-1006 were similler to those of cefteram, the MICs against S. pyogenes, and H. influenzae were ≤0.025 and 0.10 μg/ml, respectively. 3) Clinical studies. S-1108 was administered to patients with various pediatrics infections in 34 cases (upper respiratory tract infections: 12 cases, lower respiratory tract infections: 5 cases, urinary tract infections: 9 cases, skin and soft tissue infection: 6 cases, otitis media: 2 cases). Clinical efficacy rate was evaluated according to 'Standard of clinical evaluation in pediatrics field'. The responses were all good or excellent. 4) Side reactions. There were no serious adverse reactions in any cases. The above results suggest that S- 1108 is potent effective and safe agent in the pediatric field at a dose between 2~4 mg/kg (t.i.d.) a day.",
author = "H. Akita and T. Yokota and K. Sunakawa and S. Iwata and Y. Satoh",
year = "1993",
language = "English",
volume = "46",
pages = "967--977",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "11",

}

TY - JOUR

T1 - Laboratory and clinical studies on S-1108 in the pediatric field

AU - Akita, H.

AU - Yokota, T.

AU - Sunakawa, K.

AU - Iwata, S.

AU - Satoh, Y.

PY - 1993

Y1 - 1993

N2 - Laboratory and Clinical Studies on S-1108, a new oral cephem antibiotic, were carried out to evaluate its usefulness at a dose between 2 and 4 mg/kg a day for 7 to 14 days in the pediatric field. 1) Pharmacokinetic studies. S- 1108 at a dose of 2 mg/kg was administered to evaluate the pharmacokinetic parameters in 1 subject. C(max), T1/2 and AUC were 0.69 hour, 1.42 hours and 2.15 μg·hr/ml, respectively. 2) Antimicrobial activities. MICs against various clinically isolated organisms (Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Branhamella catarrhalis, Escherichia coli and Haemophilus influenzae) were determined. The MIC values of S-1006 were similler to those of cefteram, the MICs against S. pyogenes, and H. influenzae were ≤0.025 and 0.10 μg/ml, respectively. 3) Clinical studies. S-1108 was administered to patients with various pediatrics infections in 34 cases (upper respiratory tract infections: 12 cases, lower respiratory tract infections: 5 cases, urinary tract infections: 9 cases, skin and soft tissue infection: 6 cases, otitis media: 2 cases). Clinical efficacy rate was evaluated according to 'Standard of clinical evaluation in pediatrics field'. The responses were all good or excellent. 4) Side reactions. There were no serious adverse reactions in any cases. The above results suggest that S- 1108 is potent effective and safe agent in the pediatric field at a dose between 2~4 mg/kg (t.i.d.) a day.

AB - Laboratory and Clinical Studies on S-1108, a new oral cephem antibiotic, were carried out to evaluate its usefulness at a dose between 2 and 4 mg/kg a day for 7 to 14 days in the pediatric field. 1) Pharmacokinetic studies. S- 1108 at a dose of 2 mg/kg was administered to evaluate the pharmacokinetic parameters in 1 subject. C(max), T1/2 and AUC were 0.69 hour, 1.42 hours and 2.15 μg·hr/ml, respectively. 2) Antimicrobial activities. MICs against various clinically isolated organisms (Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Branhamella catarrhalis, Escherichia coli and Haemophilus influenzae) were determined. The MIC values of S-1006 were similler to those of cefteram, the MICs against S. pyogenes, and H. influenzae were ≤0.025 and 0.10 μg/ml, respectively. 3) Clinical studies. S-1108 was administered to patients with various pediatrics infections in 34 cases (upper respiratory tract infections: 12 cases, lower respiratory tract infections: 5 cases, urinary tract infections: 9 cases, skin and soft tissue infection: 6 cases, otitis media: 2 cases). Clinical efficacy rate was evaluated according to 'Standard of clinical evaluation in pediatrics field'. The responses were all good or excellent. 4) Side reactions. There were no serious adverse reactions in any cases. The above results suggest that S- 1108 is potent effective and safe agent in the pediatric field at a dose between 2~4 mg/kg (t.i.d.) a day.

UR - http://www.scopus.com/inward/record.url?scp=0027730480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027730480&partnerID=8YFLogxK

M3 - Article

C2 - 8309073

AN - SCOPUS:0027730480

VL - 46

SP - 967

EP - 977

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 11

ER -